George Tidmarsh, who helmed the FDA’s Center for Drug Evaluation and Research, resigned Sunday following a complaint by biopharma investor Kevin Tang, whose affiliated company, Aurinia Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback